(Alliance News) - Polarean Imaging PLC on Tuesday said that it intends to raise a minimum of USD10 million via a placing to institutional and other investors, and a direct subscription with the company. Read More
(Alliance News) - Stock prices in London were up at midday on Friday, hitting a record high once again as investors reacted positively to a dovish Bank of England interest rates hold. Read More
(Alliance News) - Polarean Imaging PLC on Friday said it has received its second de novo order for a new Xenon MRI system from the University of Alabama at Birmingham Hospital in the US. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
Polarean Imaging PLC - London-based medical imaging technology developer - Receives an order for a new polariser to replace the research polariser at Cincinnati Children's Hospital Medical Center. "Cincinnati Children's previously purchased the first clinical polariser and continues to demonstrate a commitment to the future of Xenon MRI for challenging lung diseases. Cincinnati Children's performs hospital clinical imaging on both children and adults (from their neighbouring partner institution, UC Medical Centre)," Polarean says. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Polarean Imaging PLC shares dropped on Thursday, after the company said it would need to find an additional USD10 million to finance its medium-term ambitions. Read More
Polarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price. Read More
Polarean Imaging PLC - London-based medical imaging technology developer - Receives its first de novo order for a new Xenoview polariser from an unnamed "top-tier" academic medical centre located in the northeast of the US. Polarean says it continues to have positive meetings and is in active negotiations with additional academic medical centres. Xenoview is a hyperpolarised contrast agent for use with magnetic imaging for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. It was approved for use in the US last year. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - Polarean Imaging PLC on Friday said that it has partnered with Vida Diagnostics Inc to work on advanced magnetic resonance imaging solutions for the lungs. Read More
(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
Polarean Imaging PLC - London-based medical imaging technology developer - Announces that following statement on August 29, the reimbursement code for the Polarean Xenoview technology has been assigned to a new technology ambulatory payment classification code which corresponds to a payment range of between USD1,201 to USD1,300 as part of the 2023 medicare hospital outpatient prospective payment system final rule. Notes the codes enables healthcare providers a path to bill for "magnetic resonance imaging with inhaled hyperpolarised xenon-129 contrast agent, chest, including preparation and administration of agent." Read More
Polarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean's Xenoview or 'xenon XE 129' magnetic resonance imaging technology. Code "enables healthcare providers a path to bill for 'magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent'." Polarean expects to be informed of the new code's payment level "in the coming weeks". Read More
Polarean Imaging PLC - London-based medical imaging technology company - Receives 510(k) clearance from the US Food & Drug Administration for its specialised magnetic resonance imaging chest coil. The coil may now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 nuclei. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News: Read More